VACCINEX, INC.
Close on Oct 19, 2026
- Market cap
- $3.22M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2021 Ended Mar 31, 2021 | May 17, 2021 | Before market open | – | – | – |
| Q4 FY2020 Ended Dec 31, 2020 | Mar 16, 2021 | Before market open | – | – | – |
Press releases
Announcements Vaccinex filed with the SEC
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
Listing notice · Other events · EX-99.1 to Form 8-K
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2
Regulation FD disclosure · EX-99.1 to Form 8-K
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of
Other events · EX-99.1 to Form 8-K
Vaccinex Reports Completion of Last Patient Visit in Randomized,
Regulation FD disclosure · EX-99.1 to Form 8-K
Agreements for Access to ActivMAb ® Antigen Virus Technology
Other events · EX-99.1 to Form 8-K
Vaccinex, Inc. Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation
Regulation FD disclosure · EX-99.1 to Form 8-K
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for
Regulation FD disclosure · EX-99.1 to Form 8-K
Vaccinex, Inc. Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted
Regulation FD disclosure · EX-99.1 to Form 8-K
Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab
Regulation FD disclosure · EX-99.1 to Form 8-K
Ipilimumab in Resectable Stage III Melanoma NCT03769155 Michael Lowe, MD, MA, FACS, FSSO Associate Professor of Surgery Emory University School of Medicine Atlanta, GA, USA 09.12.2022
Regulation FD disclosure · EX-99.1 to Form 8-K
Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in
Other events · EX-99.1 to Form 8-K
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Terrence Fisher1, E. Evans1, M. Boise1,
Regulation FD disclosure · EX-99.2 to Form 8-K
KEYNOTE-B84 Study in HNSCC June 10,
Regulation FD disclosure · EX-99.1 to Form 8-K
Vaccinex Announces $6.6 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K